From: Impact of different anti-HCV regimens on platelet count during treatment in Egyptian patients
 | SIM/SOF | SOF/RBV | Triple | p value | |||
---|---|---|---|---|---|---|---|
Count | % | Count | % | Count | % | ||
Sex | Â | Â | Â | Â | Â | Â | Â |
 Male | 26 | 45.6% | 32 | 58.2% | 38 | 67.9% | 0.057 |
 Female | 31 | 54.4% | 23 | 41.8% | 18 | 32.1% | |
Residency | Â | Â | Â | Â | Â | Â | Â |
 Urban | 34 | 59.6% | 42 | 76.4% | 35 | 62.5% | 0.138 |
 Rural | 23 | 40.4% | 13 | 23.6% | 21 | 37.5% | |
History of previous ttt | Â | Â | Â | Â | Â | Â | Â |
 ttt naïve | 54 | 94.7% | 35 | 64.8% | 42 | 75.0% | < 0.001 |
 ttt experienced | 3 | 5.3% | 19 | 35.2% | 14 | 25.0% | |
Smoking | Â | Â | Â | Â | Â | Â | Â |
 Yes | 6 | 10.5% | 7 | 12.7% | 11 | 19.6% | 0.354 |
 No | 51 | 89.5% | 48 | 87.3% | 45 | 80.4% | |
Comorbidities (diabetes and/or hypertension) | Â | Â | Â | Â | Â | Â | Â |
 Yes | 21 | 36.8% | 21 | 38.2% | 18 | 32.1% | 0.783 |
 No | 36 | 63.2% | 34 | 61.8% | 38 | 67.9% | |
Liver by ultrasound | Â | Â | Â | Â | Â | Â | Â |
 Normal | 0 | 0.0% | 2 | 3.6% | 8 | 14.3% | < 0.001 |
 Cirrhotic | 31 | 54.4% | 47 | 85.5% | 25 | 44.6% | |
 Abnormal echopattern | 26 | 45.6% | 6 | 10.9% | 23 | 41.1% | |
Spleen by ultrasound | Â | Â | Â | Â | Â | Â | Â |
 Enlarged | 28 | 49.1% | 41 | 74.5% | 35 | 62.5% | 0.021 |
 Average | 29 | 50.9% | 14 | 25.5% | 21 | 37.5% | |
Ascites by ultrasound | Â | Â | Â | Â | Â | Â | Â |
 Yes | 0 | 0.0% | 1 | 1.8% | 1 | 1.8% | 0.549 |
 No | 57 | 100.0% | 54 | 98.2% | 55 | 98.2% | |
Child score calculation | Â | Â | Â | Â | Â | Â | Â |
 A5 | 25 | 43.9% | 26 | 47.3% | 50 | 89.3% | < 0.001 |
 A6 | 32 | 56.1% | 21 | 38.2% | 4 | 7.1% | |
 B7 | 0 | 0.0% | 7 | 12.7% | 2 | 3.6% | |
 B8 | 0 | 0.0% | 1 | 1.8% | 0 | 0.0% | |
Stage of fibrosis | Â | Â | Â | Â | Â | Â | Â |
 F1 | 3 | 27.3% | 1 | 4.0% | 2 | 8.0% | 0.003 |
 F2 | 1 | 9.1% | 1 | 4.0% | 0 | 0.0% | |
 F3 | 1 | 9.1% | 4 | 16.0% | 14 | 56.0% | |
 F4 | 6 | 54.5% | 18 | 72.0% | 9 | 36.0% | |
 F5 | 0 | 0.0% | 1 | 4.0% | 0 | 0.0% | |
Stage of necroinflammatory activity | Â | Â | Â | Â | Â | Â | Â |
 A1 | 1 | 50.0% | 2 | 25.0% | 4 | 33.3% | 0.749 |
 A2 | 1 | 50.0% | 4 | 50.0% | 7 | 58.3% | |
 A3 | 0 | 0.0% | 1 | 12.5% | 0 | 0.0% | |
 A7 | 0 | 0.0% | 0 | 0.0% | 1 | 8.3% | |
 A10 | 0 | 0.0% | 1 | 12.5% | 0 | 0.0% | |
Week 4 HCV RNA by PCR | Â | Â | Â | Â | Â | Â | Â |
 Positive | 3 | 5.3% | 7 | 12.7% | 2 | 3.6% | 0.183 |
 Negative | 54 | 94.7% | 48 | 87.3% | 54 | 96.4% | |
Week 12 HCV RNA by PCR | Â | Â | Â | Â | Â | Â | Â |
 Positive | 2 | 3.6% | 1 | 1.8% | 0 | 0.0% | 0.325 |
 Negative | 53 | 96.4% | 54 | 98.2% | 56 | 100.0% | |
HCV antiviral dose modification | Â | Â | Â | Â | Â | Â | Â |
 No | 57 | 100.0% | 54 | 98.2% | 51 | 91.1% | 0.025 |
 Modified | 0 | 0.0% | 1 | 1.8% | 5 | 8.9% |